| Market Cap | 745M 641M 601M 550M 1.03B 70.39B 1.03B 7.11B 2.77B 35.97B 2.8B 2.74B 116B | P/E 2026 * |
11.2x | P/E 2027 * | 14x |
|---|---|---|---|---|---|
| Enterprise Value | 745M 641M 601M 550M 1.03B 70.39B 1.03B 7.11B 2.77B 35.97B 2.8B 2.74B 116B | EV / Sales 2026 * |
4.86x | EV / Sales 2027 * | 4.19x |
| Free-Float |
96.19% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : KemPharm, Inc.
| 1 day | -4.32% |
| Manager | Title | Age | Since |
|---|---|---|---|
Neil McFarlane
CEO | Chief Executive Officer | 53 | 09/10/2023 |
Justin Renz
DFI | Director of Finance/CFO | 54 | 08/03/2026 |
Rahsaan Thompson
CMP | Compliance Officer | 55 | 24/06/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Tamara Favorito
CHM | Chairman | 67 | 07/05/2023 |
Douglas Calder
BRD | Director/Board Member | 59 | 24/04/2023 |
Corey Watton
BRD | Director/Board Member | 56 | 24/04/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.32% | +29.70% | - | - | 745M | |
| +0.46% | +1.87% | +80.97% | +38.69% | 376B | |
| -1.38% | -3.14% | +25.21% | -19.54% | 69.66B | |
| +1.00% | +3.59% | +48.04% | +158.66% | 12.57B | |
| -1.09% | -9.76% | -8.91% | -9.69% | 8.18B | |
| +0.12% | -1.82% | -17.71% | +5.24% | 4.98B | |
| +0.12% | -1.57% | -31.08% | +21.23% | 4.47B | |
| +2.70% | -4.51% | -34.43% | -1.03% | 3.08B | |
| -0.14% | -0.50% | -2.14% | +35.33% | 2.56B | |
| +0.13% | -8.50% | -26.21% | -17.50% | 2.01B | |
| Average | -0.24% | -2.22% | +3.75% | +23.49% | 53.71B | |
| Weighted average by Cap. | +0.18% | -1.12% | +66.88% | +31.59% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 153M 132M 124M 113M 211M 14.49B 213M 1.46B 570M 7.41B 576M 563M 23.85B | 178M 153M 143M 131M 245M 16.8B 247M 1.7B 661M 8.58B 667M 653M 27.65B |
| Net income | 68.14M 58.63M 55.02M 50.34M 93.95M 6.44B 94.7M 651M 253M 3.29B 256M 250M 10.6B | 55.27M 47.55M 44.63M 40.83M 76.21M 5.22B 76.81M 528M 206M 2.67B 208M 203M 8.6B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
